You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
輝瑞嬰兒呼吸道合胞病毒疫苗獲美FDA支持 8月前或批面世
阿思達克 05-19 05:25
輝瑞(Pfizer)(PFE.US)初生嬰兒免受呼吸道合胞病毒(RSV)疫苗獲美國品和藥物管理局(FDA)支持,為全球首隻相關疫苗獲FDA支持。FDA或於今年8月高峰期之前批准該疫苗可用於孕婦身上,以保護初生嬰兒受感染,在主導該病毒免疫接種中領先同業。 美國FDA委員會所有14名成員均認同該疫苗對孕婦有效,但在安全問題中,10名小組成員認同安全,4名成員指安全數據不充分,認為輝瑞應進一步研究早產風險。 輝瑞目前正與其他藥廠競爭RSV市場,以彌補新冠肺炎疫苗收入大減,RSV市場預計將增長至超過100億美元。 輝瑞周四(18日)收市跌0.7%,消息公布後,盤後股價微升0.08%。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account